Publications

Selected publications:

  • Virtanen, L., Holm, E., Halme, M., West, G., Lindholm, F., Gullmets, J., Irjala, J., Heliö, T., Padzik, A., Meinander, A., Eriksson, J. E., & Taimen, P. (2023). Lamin A/C phosphorylation at serine 22 is a conserved heat shock response to regulate nuclear adaptation during stress. Journal of cell science 136:jcs259788. https://doi.org/10.1242/jcs.259788
  • Le Dour, C., Chatzifrangkeskou, M., Macquart, C., Magiera, M. M., Peccate, C., Jouve, C., Virtanen, L., Heliö, T., Aalto-Setälä, K., Crasto, S., Cadot, B., Cardoso, D., Mougenot, N., Adesse, D., Di Pasquale, E., Hulot, J. S., Taimen, P., Janke, C., & Muchir, A. (2022). Actin-microtubule cytoskeletal interplay mediated by MRTF-A/SRF signaling promotes dilated cardiomyopathy caused by LMNA mutations. Nature communications 13:7886. https://doi.org/10.1038/s41467-022-35639-x
  • West G, Turunen M, Aalto A, Virtanen L, Li S-P, Heliö T, Meinander A and Taimen P (2022). A heterozygous p.S143P mutation in LMNA associates with proteasome dysfunction and enhanced autophagy-mediated degradation of mutant lamins A and C. Frontiers in Cell and Deveopmental Biology 10:932983. http://doi.org/10.3389/fcell.2022.932983
  • Talvitie EM, Liljeroos L, Vilhonen H, Orte K, Leivo I, Kallajoki M, Taimen P (2022). Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis. Neoplasia 32:100832. http://doi.org/10.1016/j.neo.2022.100832
  • Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, Verhoeff JJC, Taimen P, Aronen HJ, Knaapila J, Montoya Perez I, Ettala O, Stabile A, Gandaglia G, Fossati N, Martini A, Cucchiara V, Briganti A, Lantz A, Picker W, Haug ES, Nordström T, Tanaka MB, Reddy D, Bass E, van Rossum PSN, Wong K, Tam H, Winkler M, Gordon S, Qazi H, Boström PJ, Jambor I, Ahmed HU (2022). Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. European Urology 10:S0302-2838(22)02537-4. http://doi.org/10.1016/j.eururo.2022.07.022
  • Beheshti M, Taimen P, Kemppainen J, Jambor I, Müller A, Loidl W, Kähkönen E, Käkelä M, Berndt M, Stephens AW, Minn H, Langsteger W (2022). Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study. European Radiology. http://doi.org/10.1007/s00330-022-08982-2
  • Ouellet V, Erickson A, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, Bova GS, Lamminen T, Achtman AH, Buzza M, Kouspou MM, Bigler SA, Zhou X, Freedland SJ, Mes-Masson AM, Garraway IP, Trock BJ, Taimen P, Saad F, Mirtti T, Knudsen BS, De Marzo AM (2022). The Movember Global Action Plan 1 (GAP1) – Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiology, Biomarkers & Prevention 31:715–727. https://doi.org/10.1158/1055-9965.EPI-21-0600
  • Blomqvist M, Koskinen I, Löyttyniemi E, Mirtti T, Boström PJ, Taimen P (2021). Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. Scientific Reports 11:13684. https://doi.org/10.1038/s41598-021-93245-1
  • Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M, Rinta-Kiikka I, Kajander S, Schildt J, Saukko E, Noponen T, Saunavaara J, Dean PB, Sequeiros RB, Aronen HJ, Kemppainen J, Seppänen M, Boström PJ, Ettala O (2021). Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 48:2951-2959. https://doi.org/10.1007/s00259-021-05296-1
  • Talvitie EM, Vilhonen H, Kurki S, Karlsson A, Orte K, Almangush A, Mohamed H, Liljeroos L, Singh Y, Leivo I, Laitinen T, Kallajoki M, Taimen P (2020). High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study. Neoplasia 22:333-342. https://doi.org/10.1016/j.neo.2020.05.004
  • Anttinen M, Yli-Pietilä E, Suomi V, Mäkelä P, Sainio T, Saunavaara J, Eklund L, Blanco Sequeiros R, Taimen P*, Boström PJ* (2019). Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. International Journal of Hyperthermia 36:915-925. https://doi.org/10.1080/02656736.2019.1652773
  • Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P (2019). Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. European Urology 76:430-434. https://doi.org/10.1016/j.eururo.2019.06.016
  • Shah D, Virtanen L, Prajapati C, Kiamehr M, Gullmets J, West G, Kreutzer J, Pekkanen-Mattila M, Heliö T, Kallio P, Taimen P*, Aalto-Setälä K* (2019). Modeling of LMNA-Related Dilated Cardiomyopathy Using Human Induced Pluripotent Stem Cells. Cells 8:pii: E594. https://doi.org/10.3390/cells8060594
  • Saarinen I, Jambor I, Kim M, Kuisma A, Kemppainen J, Merisaari H, Eskola O, Koskenniemi AR, Perez IM, Boström P, Taimen P*, Minn H* (2019). Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. EJNMMI Research. 9:50. https://doi.org/10.1186/s13550-019-0518-5
  • Pietilä M, Sahgal P, Peuhu E, Jäntti NZ, Paatero I, Närvä E, Al-Akhrass H, Lilja J, Georgiadou M, Andersen OM, Padzik A, Sihto H, Joensuu H, Blomqvist M, Saarinen I, Boström PJ, Taimen P, Ivaska J (2019). SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nature Communications. 10:2340. https://doi.org/10.1038/s41467-019-10275-0
  • Merisaari H, Jambor I, Ettala O, Boström PJ, Montoya Perez I, Verho J, Kiviniemi A, Syvänen K, Kähkönen E, Eklund L, Pahikkala T, Vainio P, Saunavaara J, Aronen HJ, Taimen P (2019). IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. Journal of Magnetic Resonance Imaging. 50:1641-50. https://doi.org/10.1002/jmri.26727
  • West G, Gullmets J, Virtanen L, Li SP, Keinänen A, Shimi T, Mauermann M, Heliö T, Kaartinen M, Ollila L, Kuusisto J, Eriksson JE, Goldman RD, Herrmann H, Taimen P (2016) Deleterious assembly of the lamin A/C mutant p.S143P causes ER stress in familial dilated cardiomyopathy. Journal of Cell Science 129:2732-43. https://doi.org/10.1242/jcs.184150
  • Alastalo TP, West G, Li SP, Keinänen A, Helenius M, Tyni T, Lapatto R, Turanlahti M, Heikkilä P, Kääriäinen H, Laakso M, Mauermann M, Herrmann H, Pihkala J, Taimen P (2015). LMNA Mutation c.917T>G (p.L306R) Leads to Deleterious Hyper-Assembly of Lamin A/C and Associates with Severe Right Ventricular Cardiomyopathy and Premature Aging. Human Mutation 36:694–703. https://doi.org/10.1002/humu.22793

All publications: https://pubmed.ncbi.nlm.nih.gov/?term=taimen+p&sort=date